Retroviral vectors
Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.
1. A lentivirus-based retroviral vector production system for producing a replication defective retroviral vector, wherein the retroviral vector production system comprises an expression construct encoding a lentivirus-based retroviral vector genome, and a separate expression construct or constructs encoding gag, pol, and an envelope protein, wherein the retroviral vector production system lacks nucleic acid sequences encoding functional tat, and wherein the retroviral vector production system is capable of producing a replication defective retroviral vector.
2. the retroviral production system according to claim 1 , wherein the nucleic acid sequences encoding tat are absent or disrupted in the vector system.
3. The retroviral vector production system according to claim 1 , further comprising a nucleic acid sequence encoding functionally active rev or RRE-type sequences.
4. The retroviral vector production system according to claim 3 , wherein at least one RRE-type sequence is a constitutive transport element (CTE).
5. The retroviral vector production system according to claim 4 , wherein the CTE is Mason Pfizer monkey virus CTE.
6. The retroviral vector production system according to claim 1 , further comprising at least one nucleotide sequence of interest (NOI).
7. The retroviral vector production system according to claim 6 , wherein the at least one NOI encodes a therapeutic protein or gene product of interest.
8. A method for producing a replication defective retroviral vector comprising at least one NOI, comprising contacting the retroviral vector production system of claim 6 with a cell, thereby producing the replication defective retroviral vector.
9. An isolated cell comprising the retroviral vector production system of claim 1 .
10. A composition comprising the retroviral vector production system of claim 1 and a carrier.
11. The retroviral vector production system according to claim 1 , wherein the system comprises separate DNA constructs which encode: (i) the lentivirus-based retroviral vector genome, (ii) gag and pol proteins, and (iii) an envelope protein.
12. The retroviral vector production system according to claim 1 , wherein the lentivirus-based retroviral vector genome comprises an operable promoter.
13. The retroviral vector production system according to claim 12 , wherein the promoter is a non-retroviral promoter.
14. The retroviral vector production system according to claim 1 , wherein the envelope protein is VSV-G.
15. The retroviral vector production system according to claim 1 , wherein the retroviral vector production system is based on HIV-1.
16. A set of separate DNA constructs comprising a DNA construct which encodes a replication-defective lentivirus-based retroviral vector genome, a DNA construct which encodes gag and pol proteins, and a DNA construct which encodes an envelope protein, wherein the set of DNA constructs lacks nucleic acid sequences encoding functional Tat.
17. The set of separate DNA constructs according to claim 16 , further comprising a DNA construct which encodes a functionally active rev or RRE-type sequences.
18. The set of separate DNA constructs according to claim 16 , wherein the DNA construct encoding the lentivirus-based retroviral vector genome further comprises at least one NOI.
19. A method for producing a replication defective retroviral vector, comprising expressing in a cell the retroviral vector production system according to claim 1 , thereby producing the replication defective retroviral vector.